(Q21032525)

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; a study conducted in 1996 in the French Army

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of plasmodium falciparum malaria in non-immune travelers and expatriates [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Chloroquine induced mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

21 January 2018

Mefloquine prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Malaria risk in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Travel medicine considerations for North American immigrants visiting friends and relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Controversies and misconceptions in malaria chemoprophylaxis for travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Serious problems with antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Severe imported malaria in adults: a retrospective study of 32 cases admitted to intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Extracts from "Clinical Evidence". Malaria: prevention in travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Safety evaluation of the drugs available to prevent malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Mefloquine for preventing malaria in non-immune adult travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Prevention and self-treatment of traveler's diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Malaria Prevention in Short-Term Travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Uncertainty method improved on best-worst case analysis in a binary meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Insecticide-treated nets for preventing malaria in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Drugs for preventing malaria in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Malaria: progress, perils, and prospects for eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Imported Falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Spectacular suicide associated with mefloquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Subacute clinical forms of Plasmodium falciparum malaria in travelers receiving chloroquine-proguanil prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Preventing malaria in travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Malaria in travelers: a review of the GeoSentinel surveillance network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Insecticide-treated bed nets and curtains for preventing malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Malaria: still a threat to travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Chemoprophylaxis and intermittent treatment for preventing malaria in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Risk factors for malaria in UK travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Cardiac effects of antimalarial treatment with halofantrine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Neuropsychiatric Adverse Effects of Mefloquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Malaria chemoprophylaxis in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Risk of malaria in British residents returning from malarious areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Ten-year Experience with Imported Malaria in Bergamo, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Malaria chemoprophylaxis: strategies for risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Randomized controlled trial of doxycycline prophylaxis against leptospirosis in an endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Modern malaria chemoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Mefloquine in the Prophylaxis of P. Falciparum Malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Chloroquine-resistant Plasmodium falciparum infections among UK travellers returning with malaria after chloroquine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Mefloquine neurotoxicity: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Neuropsychiatric events during prophylactic use of mefloquine before travelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

21 January 2018

Two worlds of malaria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

An efficacy trial of doxycycline chemoprophylaxis against leptospirosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

7 January 2021

Antimicrobial prophylaxis of travelers' diarrhea: a selected summary.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

7 January 2021

Doxycycline propylaxis for human scrub typhus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

7 January 2021

Absence of tooth staining with doxycycline treatment in young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

7 January 2021

The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

7 January 2021

A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

7 January 2021

Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006491.PUB2

7 January 2021

Vaccines for preventing malaria (pre-erythrocytic)

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD006491.PUB2

Vaccines for preventing malaria (SPf66)

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD006491.PUB2

[Malaria surveillance in Germany 2000/2001--results and experience with a new reporting system]

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD006491.PUB2

Vaccines for preventing malaria (blood-stage)

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD006491.PUB2